A Prospective, Multicenter, Open-Label, Single-Arm, prescription event monitoring, observational study to assess the efficacy, safety and tolerability of Enteral Feeding with High Protein, high-calorie and Semi-elemental Formula (CELNUTRA 2.0) and Kitchen feed in the Intensive Care Unit (ICU) Subjects (Protocol: CELNUTRA 2.0 - 01/2022; Version: 01, 01/07/2022)

ucgenex lifesciences Pvt. Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月29日

研究概览

暂无简介。

•1. All patients who are admitted to the intensive care unit (ICU) including gastrointestinal incompliant subjects who need enteral tube feeding along with other nourishment.
•2. Patients >=18 years old subjects where enteral nutrition is begun by the attending physician during the first 48 hours, and are expected to require nutritional support for 1 week or more.
•3. Patients whose NUTRIC score and body composition is analyzed at admission and at discharge using the bioelectrical impedance analysis (BIA).
•4. Patients legally acceptable representative provide informed consent for collection of patients information for research purpose.

•1. Pregnant and breast-feeding women
•2. Multiorgan failure
•3. Not expected to survive due to the severity of their illness or traumatic injuries
•4. Short bowel syndrome
•5. Enterocutaneous fistula
•6. Intestinal ischemia
•7. Massive gastrointestinal haemorrhage
•8. Gastrointestinal resection
•9. Given parenteral nutrition
•10. The patient is acutely impacted or constipated, or has intestinal obstruction
•11. Had severe intolerance for enteral nutrition or formula
•12. The patient has an allergy or intolerance to any ingredient in the study product

发起方

ucgenex lifesciences Pvt. Limited